Evaluation of coverage of mass drug administration programme conducted in Nalgonda district of Telangana state

Authors

  • Praveena Ganapa Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India
  • Kishore Y. Jothula Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India
  • Vishweswara Rao Guthi Department of Community Medicine, Sri Padmavathi Medical College for Women, Tirupati, Andhra Pradesh, India
  • P. Abhishek Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India
  • V. Jyothi Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India
  • D. Sreeharshika Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India
  • Pramodh Reddy Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20184786

Keywords:

Lymphatic filariasis, Mass drug administration, Coverage rate, Compliance rate

Abstract

Background: Lymphatic filariasis has been a major public health problem in India. Government of India during 2004 initiated Mass Drug Administration (MDA) with annual single dose of DEC tablets to all the population living at the risk of filariasis. Nalgonda is endemic district where MDA programme is undertaken every year to eliminate lymphatic filariasis. The present study was undertaken to evaluate the coverage and compliance rates of the MDA programme conducted during January 2018.

Methods: The guidelines of National Vector Borne Disease Control Programme (NVBDCP) were used to select a total of 129 households from four clusters (three rural and one urban). Each household was visited by a team and data was recorded on pre-structured questionnaire available in operational guidelines manual of NVBDCP. Data analyzed by SPSS version 22.

Results: Total of 129 households were included in the study, Among the 523 study population, only 494 were eligible population to receive MDA. Current study shows that coverage rate was 79.84% and compliance rate was 84.6%. Fear of side effects was most common reason for noncompliance.

Conclusions: Efforts should be made to improve coverage rates by involving more human resources, supervision and incentives. Though compliance rates were higher than required there is need to maintain these rates by IEC activities and community participation. 

Author Biographies

Praveena Ganapa, Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India

Department of Community Medicine

Assistant Professor

Kishore Y. Jothula, Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India

Department of Community Medicine

Associate Professor

Vishweswara Rao Guthi, Department of Community Medicine, Sri Padmavathi Medical College for Women, Tirupati, Andhra Pradesh, India

Department of Community Medicine

Assistant Professor

P. Abhishek, Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India

Department of Community Medicine

Post Graduate

V. Jyothi, Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India

Department of Community Medicine

Post Graduate

D. Sreeharshika, Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India

Department of Community Medicine
Tutor

Pramodh Reddy, Department of Community Medicine, Kamineni Institute of Medical Sciences, Narketpally, Telangana, India

Department of Community Medicine
Tutor

References

National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Lymphatic Filariasis. Magnitude of disease. Website: Available at: http://nvbdcp.gov.in/ fil10.html. Accessed on 3 June 2018.

WHO: Lymphatic Filariasis fact sheet WHO Updates. Available at: http://www.who.int/media centre/factsheets/fs102/e n/. Accessed on 3 June 2018.

National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Lymphatic Filariasis. Upscaling of mass drug administration. Website: Available at: http://nvbdcp.gov.in/filariasis-new.html. Accessed on 3 June 2018.

Ravish KS, Ranganath TS, Riyaz BS. Coverage and compliance of Mass Drug Administration for elimination of lymphatic filariasis in endemic areas of Bijapur district, Karnataka. Int J Basic Med Sci. 2011;2:86-9.

Kumar P, Prajapati PB, Saxena D, Kavishwar AB, George K. An evaluation of coverage and compliance of Mass Drug Administration for elimination of lymphatic filariasis in endemic areas of Gujarat. Indian J Community Med. 2008;33:38-42.

Ray KP, Mitra K, Chatterjee A, Jana PK, Bhattacharya S, Lahiri SK. A study on coverage, compliance and awareness about Mass Drug Administration for elimination of lymphatic filariasis in a district of West Bengal, India. J Vector Borne Dis. 2011;48:101-4.

Ministry of health and family welfare. National vector borne disease control programme: guidelines on filariasis control in India and its elimination, 2009. Available at: www.nvbdcp.gov.in/ Doc/Guidelines-FilariasisElimination_India.pdf. Accessed on 3 June 2018.

Available at: http://www.who.int/gho/neglected_ diseases/lymphatic_filariasis/en/. Accessed on 3 June 2018.

National Roadmap for Elimination of Lymphatic Filariasis (ELF). Available at: nvbdcp.gov.in/ iec.html. Accessed on 3 June 2018.

Saiprasad GS, Takalkar AA, Prasad VG, Nirgude AS, Naik PR, Palve S. Evaluation of Mass Drug Administration in Elimination of Lymphatic Filariasis in Nalgonda District. Indian J Public Health. 2010;54(4):104-99.

Nirgude AS, Naik PR, Nagaraj K, Reshmi SS, Takalkar AA, Prasad VG. Evaluation of coverage and compliance of Mass Drug Administration programme 2011 for Elimination of Lymphatic Filariasis in Nalgonda District of Andhra Pradesh, India. National J Community Med. 2012;3(2):288-93.

Malhotra V, Prasad VG, Suguna D, Kishore Yadav J, Nagaraj K, Bhayya S. Evaluation of coverage and compliance of Mass drug administration programme for elimination of lymphatic filariasis in Nalgonda district of Telangana state. IJBAMR. 2014;1(1):106.

Prasad VG, Malhotra VM, Kishore YJ, Prasad K, Nagaraj K. Evaluation of mass drug administration programme for elimination of lymphatic filariasis in Nalgonda district of Telangana. Int J Health Sci Res. 2015;5(5):11-6.

Jothula KY, Naidu NK, Malhotra VM, Prasad VG, Kabra PR, Nagaraj K. Evaluation of mass drug administration programme for elimination of lymphatic filariasis in Nalgonda district, Telangana, India. Int J Community Med Public Health. 2016;3(8):2008-12.

Nujum ZT. Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India. Int Health. 2011;3(1):22-6.

Ghosh S, Samanta A, Kole S. Mass drug administration for elimination of lymphatic ilariasis: Recent experiences from a district of West Bengal, India. Trop Parasitol. 2013;3:67-71.

Patel PK. Mass drug administration coverage evaluation survey for lymphatic Filariasis in Bagalkot and Gulbarga districts. Indian J Community Med. 2012;37:101-6.

Chattopadhyay D, Bisoi S, Basu M, Dutta S, Chatterjee T, Roy S. Annual mass drug administration to eliminate lymphatic filariasis: A study in Purba district of West Bengal. Int J Basic Applied Med Sci. 2012;2:43-51.

Downloads

Published

2018-11-24

How to Cite

Ganapa, P., Jothula, K. Y., Guthi, V. R., Abhishek, P., Jyothi, V., Sreeharshika, D., & Reddy, P. (2018). Evaluation of coverage of mass drug administration programme conducted in Nalgonda district of Telangana state. International Journal Of Community Medicine And Public Health, 5(12), 5178–5183. https://doi.org/10.18203/2394-6040.ijcmph20184786

Issue

Section

Original Research Articles